Mayo Clinic Laboratory and pathology research roundup: September 28
Share this:
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Featured Abstract
Effect of probiotics on incident ventilator-associated pneumonia in critically Ill patients: A randomized clinical trial.
Growing interest in microbial dysbiosis during critical illness has raised questions about the therapeutic potential of microbiome modification with probiotics. Prior randomized trials in this population suggest that probiotics reduce infection, particularly ventilator-associated pneumonia (VAP), although probiotic-associated infections have also been reported. Via PubMed
Published to PubMed This Week
- Performance assessment of DNA sequencing platforms in the ABRF next-generation sequencing study.
Nature Biotechnology - Dementia with lewy bodies research consortia: A global perspective from the ISTAART lewy body dementias professional interest area working group.
Alzheimer's and Dementia - Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.
Nature Communications - Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes.
Blood Cancer Journal - Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.
American Journal of Hematology - Antibacterial resistance leadership group 2.0: back to business.
Clinical Infectious Disease - Association between proposed definitions of clinical remission/response and well-being in patients with crohn's disease.
The Journal of Crohn's and Colitis - High-sensitivity troponin: revealing the ominous implications of myocardial injury in critical illness.
Critical Care Medicine - Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours.
Amyloid - Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial.
Jama Oncology
